Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Ambrosioni J, Rojas Liévano J, Berrocal L, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Ugarte A, Chivite I, Leal L, de Lazzari E, Miró JM, Blanco JL, Martinez E, Mallolas J. Ambrosioni J, et al. Among authors: berrocal l. J Antimicrob Chemother. 2022 Mar 31;77(4):1133-1139. doi: 10.1093/jac/dkab481. J Antimicrob Chemother. 2022. PMID: 35040990
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group. Nomah DK, et al. J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273. doi: 10.1093/jac/dkac177. J Antimicrob Chemother. 2022. PMID: 35678461 Free PMC article.
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
Immunological and virological findings in a patient with exceptional post-treatment control: a case report.
Climent N, Ambrosioni J, González T, Xufré C, Casadellà M, Noguera-Julian M, Paredes R, Plana M, Grau-Expósito J, Mallolas J, Alcamí J, Sánchez-Palomino S, Miró JM; Hospital Clínic de Barcelona PHI investigators. Climent N, et al. Lancet HIV. 2023 Jan;10(1):e42-e51. doi: 10.1016/S2352-3018(22)00302-2. Epub 2022 Oct 27. Lancet HIV. 2023. PMID: 36354046
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
Martínez-Serra A, De Lazzari E, Berrocal L, Foncillas A, De La Mora L, Inciarte A, Chivite I, González-Cordón A, Martínez-Rebollar M, Torres B, Laguno M, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Martínez-Serra A, et al. Among authors: berrocal l. J Antimicrob Chemother. 2023 Aug 2;78(8):1955-1962. doi: 10.1093/jac/dkad189. J Antimicrob Chemother. 2023. PMID: 37311224
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands.
Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J; PISCIS Cohort Group. Bruguera A, et al. Int J Epidemiol. 2023 Aug 2;52(4):e241-e252. doi: 10.1093/ije/dyad083. Int J Epidemiol. 2023. PMID: 37403345 No abstract available.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).
Inciarte A, Ugarte A, Martínez-Rebollar M, Torres B, Fernández E, Berrocal L, Laguno M, De la Mora L, De Lazzari E, Callau P, Chivite I, González-Cordón A, Solbes E, Rico V, Barrero L, Blanco JL, Martínez E, Ambrosioni J, Mallolas J; DORAVIPEP Study Group. Inciarte A, et al. Among authors: berrocal l. Open Forum Infect Dis. 2023 Jul 19;10(8):ofad374. doi: 10.1093/ofid/ofad374. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539061 Free PMC article.
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A, Borjabad B, Berrocal L, Blanch J, Inciarte A, Chivite I, Gonzalez-Cordon A, Torres B, Ambrosioni J, Martinez-Rebollar M, Laguno M, De La Mora L, Foncillas A, Sempere A, Rodriguez A, Solbes E, Llobet R, Miro JM, Mallolas J, Blanco JL, De Lazzari E, Martinez E. Rocabert A, et al. Among authors: berrocal l. J Antimicrob Chemother. 2023 Dec 1;78(12):2961-2967. doi: 10.1093/jac/dkad338. J Antimicrob Chemother. 2023. PMID: 37875023
31 results